Medical Director [clinicaltrials_resource:8a691d219dceada090b080eff9a091fc]
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) [clinicaltrials:NCT00168714]clinicaltrials:NCT00297232clinicaltrials:NCT00306592clinicaltrials:NCT00390221clinicaltrials:NCT00420212clinicaltrials:NCT00451451Pregnancy Exposure Registry for Tysabri® [clinicaltrials:NCT00472992]TYSABRI Global Observational Program in Safety [clinicaltrials:NCT00477113]TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World [clinicaltrials:NCT00483847]clinicaltrials:NCT00493298clinicaltrials:NCT00516893clinicaltrials:NCT00536120Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) [clinicaltrials:NCT00559702]clinicaltrials:NCT00616434clinicaltrials:NCT00675428CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring [clinicaltrials:NCT00707512]Phase I/IIa Study of FIXFc in Hemophilia B Patients [clinicaltrials:NCT00716716]A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State [clinicaltrials:NCT00744679]clinicaltrials:NCT00784836A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function [clinicaltrials:NCT00818038]clinicaltrials:NCT00828204clinicaltrials:NCT00835770clinicaltrials:NCT00870740clinicaltrials:NCT00871780Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS [clinicaltrials:NCT00884481]clinicaltrials:NCT00906399Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants [clinicaltrials:NCT00961766]clinicaltrials:NCT01027364clinicaltrials:NCT01051349clinicaltrials:NCT01058005clinicaltrials:NCT01064401A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis [clinicaltrials:NCT01065090]clinicaltrials:NCT01070823clinicaltrials:NCT01070836A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers [clinicaltrials:NCT01119781]clinicaltrials:NCT01156311clinicaltrials:NCT01181128JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) [clinicaltrials:NCT01185717]Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy [clinicaltrials:NCT01211639]clinicaltrials:NCT01211665
overall official [clinicaltrials_vocabulary:overall-official]
Medical Director [clinicaltrials_resource:8a691d219dceada090b080eff9a091fc]
Bio2RDF identifier
8a691d219dceada090b080eff9a091fc
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8a691d219dceada090b080eff9a091fc
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
clinicaltrials@biogen.com
clinicaltrials@biogenidec.com
last name [clinicaltrials_vocabulary:last-name]
Medical Director
phone [clinicaltrials_vocabulary:phone]
310-825-3264
720-777-1319
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:8a691d219dceada090b080eff9a091fc
title
Medical Director
@en
type
label
Medical Director [clinicaltrials_resource:8a691d219dceada090b080eff9a091fc]
@en